Skip to main content
. 2013 Nov 15;44(1):17–26. doi: 10.3892/ijo.2013.2179

Figure 1.

Figure 1.

Kaplan-Meier survival estimate. (A) Post-progression from first line FIr-B/FOx regimen overall survival; (B) Post-progression from first line FIr-B/FOx regimen overall survival, second line treated patients versus untreated patients; (C) Second line treatment, overall patients, progression-free survival; (D) Second line treatment, overall patients, overall survival; (E) Second line treatment, KRAS wild-type versus KRAS mutant patients: (E1) Progression-free survival; (E2) Overall survival.